(Santa Clara, CA) December 4, 2023 -- Antibody Solutions, a leading provider of custom antibody services to the bio-pharamceutical market, and mAbsolve, developers of a novel Fc silencing variant, today announced a licensing deal for mAbsolve’s Fc silencing technology. The agreement provides Antibody Solutions with access to the new STR Fc silencing platform. The agreement provides Antibody Solutions clients with easy license-free access to the new STR Fc silencing platform for antibody research and development.
Fc-mediated immune effector activities are an important part of an antibody’s natural function, but in many therapeutic antibodies these interactions are not desirable and can lead to catastrophic side effects. Many approaches to eliminate effector function have been developed, but none completely silence the unwanted binding to Fc gamma receptors. The new STR Fc silencing platform, developed by mAbsolve and described in a recent PLOS One article, delivers the only truly silent Fc mutations described to date. The technology therefore has the potential to improve the safety and efficacy of therapeutic antibodies and Fc fusion proteins.
The license agreement allows Antibody Solutions to make this best-in-class Fc silencing technology available for early-stage therapeutic development and ensures its clients have the best possible starting position for further development of their lead antibody candidates.
“At Antibody Solutions, we embrace cutting-edge technologies that provide tangible benefits to our clients, and mAbsolve’s STR Fc silencing technology does precisely that,” said John Kenney, PhD, President and Co-founder of Antibody Solutions. “This innovative solution unlocks the full potential of our client's candidates by elevating their half-life, reducing immunogenicity, and enhancing formulation and stability. Our partnership with mAbsolve and the integration of STR Fc will definitely boost the effectiveness of our discovery work.”
“mAbsolve is committed to improving the safety and effectiveness of therapeutic antibodies, and we strongly believe that STR technology can be of real benefit to the majority of antibody and Fc fusion proteins in development,” said Dr. Geoff Hale, Chief Executive Officer at mAbsolve. “Our STR mutations provide a truly silent and highly developable antibody Fc region, and we are eager to widely license it to partners such as Antibody Solutions, to make the technology easily accessible for therapeutic developers around the world.”
For more information, visit the Antibody Solutions or mAbsolve websites.
About Antibody Solutions
Antibody Solutions helps biopharmaceutical companies advance their discovery of better therapeutics and diagnostics by delivering fit-for-purpose antibodies. Using its Cellestive antibody discovery platform, the company provides comprehensive project management and technical support in a fee-for-service, pay-as-you-go business model. Antibody Solutions has served more than 800 clients, including the top 10 global pharmaceutical companies, and can boast a 96% client return rate. Founded in 1995, the company is headquartered in Santa Clara, CA and serves clients worldwide. Learn more at antibody.com.
About mAbsolve Ltd.
mAbsolve founded in the UK by pioneers of therapeutic antibody development and engineering from both Oxford and Cambridge. We have experienced the clinical challenges caused by incomplete silencing of antibodies using LALA, aglycosylated or IgG4 variants. To address this we have developed a best-in-class solution for silencing of antibody effector function. Our STR technology is the only truly silent Fc. Visit www.mabsolve.com for more information.
Contact:
Debra Valsamis
Business Development Manager
Antibody Solutions
3033 Scott Boulevard
Santa Clara, CA 95054
Ph: 650-938-4300x111
